The significance of somatostatin analogues in the antiproliferative treatment of carcinomas.

[1]  S. Hankinson,et al.  S9 Biology of breast cancer risk and prognosis , 1998 .

[2]  S. Cascinu,et al.  Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. , 1997, Gastroenterology.

[3]  U. Haus,et al.  Regression of a distal bile duct carcinoma after treatment with octreotide for 6 months. , 1997, Digestion.

[4]  G. Galaktidou,et al.  The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. , 1997, Journal of experimental & clinical cancer research : CR.

[5]  G. Vitale,et al.  Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α‐2b and octreotide , 1996, Cancer.

[6]  K. O'Byrne,et al.  Somatostatin and somatostatin analogues in medullary thyroid carcinoma. , 1996, Nuclear medicine communications.

[7]  Q. Duh,et al.  Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. , 1996, The Journal of clinical endocrinology and metabolism.

[8]  T. Inoue,et al.  [Somatostatin analogue treatment for malignant hypercalcemia associated with advanced breast cancer]. , 1996, Gan to kagaku ryoho. Cancer & chemotherapy.

[9]  T. Cooke,et al.  Therapeutic potential of octreotide in the treatment of liver metastases , 1996, Anti-Cancer Drugs.

[10]  F. Boccardo,et al.  Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. , 1995, Anticancer research.

[11]  R. Goldberg,et al.  A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma , 1995, Cancer.

[12]  F. Innocenti,et al.  Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines. , 1995, Pharmacological research.

[13]  D. Morris,et al.  Octreotide reduces the kinetic index, proliferating cell nuclear antigen–maximum proliferative index, in patients with colorectal cancer , 1995, Cancer.

[14]  M. Schlumberger,et al.  Cushing’s syndrome in medullary thyroid carcinoma , 1995, Journal of endocrinological investigation.

[15]  R. Ziegler,et al.  [Therapy of metastatic medullary thyroid gland carcinoma with the somatostatin analog octreotide]. , 1995, Medizinische Klinik.

[16]  D. Morris,et al.  SMS 201.995 (Sandostatin) enhances in-vitro effects of 5-fluorouracil in colorectal cancer. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  S. Cascinu,et al.  A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. , 1995, British Journal of Cancer.

[18]  A. Barkun,et al.  Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas , 1995, Cancer.

[19]  M. Pollak,et al.  Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. , 1994, Cancer research.

[20]  J. Jeekel,et al.  Somatostatin receptor‐dependent growth inhibition of liver metastases by octreotide , 1994, The British journal of surgery.

[21]  D. Morris,et al.  Octreotide inhibits development of hepatic metastases from a human colonic cancer cell line , 1994, The British journal of surgery.

[22]  H. Friess,et al.  Role of octreotide in the treatment of pancreatic cancer. , 1994, Digestion.

[23]  K. Ain,et al.  Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. , 1994, The Journal of clinical endocrinology and metabolism.

[24]  A. Tofani,et al.  TSH suppression by octreotide in differentiated thyroid carcinoma , 1994, Clinical endocrinology.

[25]  G. Baldwin,et al.  8 Gut hormones, growth and malignancy , 1994 .

[26]  P. Malfertheiner,et al.  Treatment of advanced pancreatic cancer with high-dose octreotide , 1993, International journal of pancreatology : official journal of the International Association of Pancreatology.

[27]  H. Friess,et al.  Low‐Dose Octreotide Treatment Is Not Effective in Patients with Advanced Pancreatic Cancer , 1993, Pancreas.

[28]  G. Rollandi,et al.  LH-RH analogue treatment in adenocarcinoma of the pancreas: a phase II study. Gruppo Ligure per lo Studio del Pancreas. , 1993, Oncology.

[29]  T. Mang,et al.  Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Schally,et al.  Somatostatin Analogue RC‐160 and LH‐RH Antagonist SB‐75 Inhibit Growth of MIA PaCa‐2 Human Pancreatic Cancer Xenografts in Nude Mice , 1993, Pancreas.

[31]  M. Rieu,et al.  Paradoxical effect of somatostatin analogues on the ectopic secretion of corticotropin in two cases of small cell lung carcinoma. , 1993, Hormone Research.

[32]  D. Jaeck,et al.  Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research. , 1992, American journal of surgery.

[33]  M. Büchler,et al.  Treatment of Duct Carcinoma of the Pancreas with the LH‐RH Analogue Buserelin , 1992, Pancreas.

[34]  P. Guillou,et al.  Human pancreatic cancer cell lines do not express receptors for somatostatin. , 1992, British journal of cancer.

[35]  C. Pasquali,et al.  Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin). , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[36]  A. Bogdén,et al.  Molecular heterogeneity of somatostatin analogue BIM-23014C receptors in human breast carcinoma cells using the chemical cross-linking assay. , 1992, Cancer research.

[37]  D. Morris,et al.  SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. , 1992, Cancer research.

[38]  F. Boccardo,et al.  Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study , 1992, Cancer.

[39]  A. Hajri,et al.  Inhibition of the growth of transplanted rat pancreatic acinar carcinoma with octreotide. , 1991, European journal of cancer.

[40]  L. Kvols,et al.  Somatostatin receptors in malignant tissues , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[41]  J. Foekens,et al.  Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. , 1990, British Journal of Cancer.

[42]  A. Bogdén,et al.  Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline). , 1990, Cancer research.

[43]  S. Iacobelli,et al.  Advanced breast cancer: response to somatostatin. , 1990, Anticancer research.

[44]  D. Day,et al.  Effects of a somatostatin analogue (SMS 201‐995) on the growth and development of hepatic tumour derived by intraportal injection of Walker cells in the rat , 1989, The British journal of surgery.

[45]  J. Reubi,et al.  The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer , 1989, Cancer.

[46]  A. Andrén-sandberg.  Androgen influence on exocrine pancreatic cancer , 1989, International journal of pancreatology : official journal of the International Association of Pancreatology.

[47]  R. Murphy,et al.  Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin. , 1989, British Journal of Cancer.

[48]  A. Schally,et al.  Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[49]  A. Harris,et al.  Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. , 1989, Anticancer research.

[50]  J. P. Smith,et al.  Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. , 1988, Gastroenterology.

[51]  M. Rudin,et al.  Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995). , 1988, Cancer research.

[52]  D. Morris,et al.  Growth‐promoting action of gastrin on human colonic and gastric tumour cells cultured in vitro , 1988, The British journal of surgery.

[53]  R. Allen,et al.  Triple therapy in cadaver renal transplantation , 1988, The British journal of surgery.

[54]  J. Foekens,et al.  Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. , 1987, Cancer research.